Industries:
Biotechnology
Medical
Pharmaceutical
Health Care
Therapeutics
Biopharma
Life Science
Investor Types:
Venture Capital
Micro VC
Investment Stages:
Early Stage Venture
Location: Israel
Hadasit Bio-Holdings Ltd. ("HBL") was founded and floated on the Tel Aviv Stock Exchange (TASE : HDST ) and recently on the OTC (OTCBB : HADSY ) in order to allow public participation in the highly promising field of biotechnology.
It serves as a precedent in biotech financing - for the first time, public investment is allowed to
participate in a holding entity including companies based on IP generated by Israel’s foremost medical research center – Hadassah University Hospital ("HU").
In addition to the public holdings (54%) – including major Israeli institutional investors, HBL is held by Hadasit (www.hadasit.co.il) (36%) and Consensus Business Group (http://www.consensusbusiness.com) (10%). The traded stock, as a unique investment vehicle, provides investment exposure to a select cluster of 6 biotech companies - all based on inventions developed and owned by HU.
HBL is a publicly traded subsidiary of Hadasit Ltd. – the technology transfer company of the Hadassah University Hospital in Jerusalem, Israel. Hadasit was established for the purpose of promoting and commercializing the intellectual property (IP) and R&D capabilities generated by Hadassah, aimed at finding solutions to problems faced by modern medicine.